ACRS
NASDAQAclaris Therapeutics Inc.
News · 26 weeks40+100%
2026-03-012026-08-23
Mix1690d
- Insider7(44%)
- SEC Filings5(31%)
- Other3(19%)
- Earnings1(6%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aclaris Therapeutics Inc.SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
- SECAclaris Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- SECSEC Form S-3ASR filed by Aclaris Therapeutics Inc.S-3ASR - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- PRAclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilaris. Aclaris expects to initiate a phased multi-part Phase 2b trial of modzatinib in LP in the fourth quarter of 2026. Fast Track designation is intended to facilitate the development and expedite the review of investigational therapies that treat se
- SECSEC Form 10-Q filed by Aclaris Therapeutics Inc.10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- SECAclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- PRAclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line Results from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 and Phase 2 Trial of Bosakitug (ATI-045) - - Strong Cash Runway Expected to Enable Development of Pipeline Through the End of 2028 - WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2026 and provided a
- INSIDERChief Scientific Officer Kolbeck Roland Wilhelm converted options into 36,375 shares and covered exercise/tax liability with 12,385 shares (SEC Form 4) (withholding tax)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- INSIDERDirector Molineaux Christopher P. converted options into 11,580 shares, increasing direct ownership by 20% to 69,536 units (SEC Form 4)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- INSIDERDirector Milano Vincent converted options into 11,580 shares, increasing direct ownership by 67% to 28,896 units (SEC Form 4)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- INSIDERDirector Mehra Anand converted options into 11,580 shares, increasing direct ownership by 2% to 726,403 units (SEC Form 4)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- INSIDERDirector Humphries William D. converted options into 11,580 shares, increasing direct ownership by 35% to 45,105 units (SEC Form 4)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- INSIDERDirector Schiff Andrew N converted options into 11,580 shares, increasing direct ownership by 83% to 25,540 units (SEC Form 4)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- INSIDERDirector Gowen Maxine converted options into 11,580 shares, increasing direct ownership by 53% to 33,334 units (SEC Form 4)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- SECAclaris Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- PRAclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceWAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris T
- PRAclaris Therapeutics to Participate in the 2026 Bank of America Healthcare ConferenceWAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris' President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutic
- SECSEC Form 10-Q filed by Aclaris Therapeutics Inc.10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- SECAclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- PRAclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual Mechanism of ATI-2138 Supports Planned Phase 2b Clinical Trial in Lichen Planus - - Strong Cash Runway Expected to Enable Development of Pipeline Through 2028 - WAYNE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2026 and provided a corporate and clinical update. "Since t
- INSIDERChief Medical Officer Hall Jesse Wayne converted options into 36,375 shares and covered exercise/tax liability with 9,330 shares (SEC Form 4) to satisfy withholding tax4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- ANALYSTGuggenheim initiated coverage on Aclaris Therapeutics with a new price targetGuggenheim initiated coverage of Aclaris Therapeutics with a rating of Buy and set a new price target of $12.00
- SECAclaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
- PRAclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Estimated Half-Life of Approximately 45 Days; Unlocks Opportunity for up to Three-Month Dosing Interval - - Complete and Sustained Inhibition of TSLP-Induced and IL-4 Induced CCL17 (TARC) Provides Potential to Raise Efficacy Ceiling in Th2-Driven Diseases - - Enrollment and Dosing Ongoing in Phase 1b Trials in Asthma and Atopic Dermatitis (AD) with Top Line Results Expected in the Second Half of 2026 - - Lichen Planus Selected as Lead Indication for ATI-2138; Potential to b
- INSIDERLarge owner Leonard Braden Michael sold $1,359,000 worth of shares (300,000 units at $4.53) (SEC Form 4)4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
ACRS FAQ
7 questionsWhat does Aclaris Therapeutics Inc. do?
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases...Where does ACRS stock trade?
Aclaris Therapeutics Inc. (ACRS) is listed on NASDAQ.What sector and industry is ACRS in?
Aclaris Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aclaris Therapeutics Inc. go public?
Aclaris Therapeutics Inc. (ACRS) completed its IPO in 2015.What are analysts saying about ACRS?
Aclaris Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $1200.00 price target on 2026-05-05. Recent price targets range from $600.00 to $2000.00.What companies are similar to ACRS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ACRS side-by-side with any of them on Quantisnow.How can I track ACRS on Quantisnow?
Quantisnow aggregates Aclaris Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACRS to receive live email and push alerts on every new disclosure.